This HTML5 document contains 160 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00475/identifier/chebi/
n4http://linked.opendata.cz/resource/drugbank/company/
n26http://linked.opendata.cz/resource/drugbank/dosage/
n15http://linked.opendata.cz/resource/drugbank/mixture/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00475/identifier/wikipedia/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00475/identifier/pharmgkb/
n11http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n16http://www.rxlist.com/cgi/generic/
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00475/identifier/kegg-drug/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n25http://linked.opendata.cz/resource/drugbank/drug/DB00475/identifier/drugbank/
n13http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n8http://www.drugs.com/cdi/
n9http://linked.opendata.cz/resource/drugbank/property/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00475/identifier/national-drug-code-directory/
n12http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/atc/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00475
rdf:type
n3:Drug
n3:description
An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal. [PubChem]
n3:dosage
n26:271B5990-363D-11E5-9242-09173F13E4C5 n26:271B5991-363D-11E5-9242-09173F13E4C5 n26:271B5992-363D-11E5-9242-09173F13E4C5 n26:271B5993-363D-11E5-9242-09173F13E4C5 n26:271B5994-363D-11E5-9242-09173F13E4C5 n26:271B5995-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Skerritt JH, Johnston GA: Enhancement of GABA binding by benzodiazepines and related anxiolytics. Eur J Pharmacol. 1983 May 6;89(3-4):193-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6135616 # Oishi R, Nishibori M, Itoh Y, Saeki K: Diazepam-induced decrease in histamine turnover in mouse brain. Eur J Pharmacol. 1986 May 27;124(3):337-42. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/3089825 # Earley JV, Fryer RI, Ning RY: Quinazolines and 1,4-benzodiazepines. LXXXIX: Haptens useful in benzodiazepine immunoassay development. J Pharm Sci. 1979 Jul;68(7):845-50. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/458601 # Olive G, Dreux C: [Pharmacologic bases of use of benzodiazepines in pereinatal medicine] Arch Fr Pediatr. 1977 Jan;34(1):74-89. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/851373 # Vozeh S: [Pharmacokinetic of benzodiazepines in old age] Schweiz Med Wochenschr. 1981 Nov 21;111(47):1789-93. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/6118950
n3:group
approved illicit
n3:halfLife
24-48 hours
n3:indication
For the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety.
n3:manufacturer
n4:271B597B-363D-11E5-9242-09173F13E4C5 n4:271B597C-363D-11E5-9242-09173F13E4C5 n4:271B5979-363D-11E5-9242-09173F13E4C5 n4:271B597A-363D-11E5-9242-09173F13E4C5 n4:271B5977-363D-11E5-9242-09173F13E4C5 n4:271B5978-363D-11E5-9242-09173F13E4C5 n4:271B5975-363D-11E5-9242-09173F13E4C5 n4:271B5976-363D-11E5-9242-09173F13E4C5 n4:271B597F-363D-11E5-9242-09173F13E4C5 n4:271B5980-363D-11E5-9242-09173F13E4C5 n4:271B597D-363D-11E5-9242-09173F13E4C5 n4:271B597E-363D-11E5-9242-09173F13E4C5 n4:271B596B-363D-11E5-9242-09173F13E4C5 n4:271B596C-363D-11E5-9242-09173F13E4C5 n4:271B5969-363D-11E5-9242-09173F13E4C5 n4:271B596A-363D-11E5-9242-09173F13E4C5 n4:271B5973-363D-11E5-9242-09173F13E4C5 n4:271B5974-363D-11E5-9242-09173F13E4C5 n4:271B5971-363D-11E5-9242-09173F13E4C5 n4:271B5972-363D-11E5-9242-09173F13E4C5 n4:271B596F-363D-11E5-9242-09173F13E4C5 n4:271B5970-363D-11E5-9242-09173F13E4C5 n4:271B596D-363D-11E5-9242-09173F13E4C5 n4:271B596E-363D-11E5-9242-09173F13E4C5
owl:sameAs
n11:DB00475 n19:DB00475
dcterms:title
Chlordiazepoxide
adms:identifier
n18:Chlordiazepoxide n20:0555-0158-02 n21:PA448932 n23:D00267 n24:3611 n25:DB00475
n3:mechanismOfAction
Chlordiazepoxide binds to stereospecific benzodiazepine (BZD) binding sites on GABA (A) receptor complexes at several sites within the central nervous system, including the limbic system and reticular formation. This results in an increased binding of the inhibitory neurotransmitter GABA to the GABA(A) receptor.BZDs, therefore, enhance GABA-mediated chloride influx through GABA receptor channels, causing membrane hyperpolarization. The net neuro-inhibitory effects result in the observed sedative, hypnotic, anxiolytic, and muscle relaxant properties.
n3:packager
n4:271B5949-363D-11E5-9242-09173F13E4C5 n4:271B594A-363D-11E5-9242-09173F13E4C5 n4:271B5948-363D-11E5-9242-09173F13E4C5 n4:271B595C-363D-11E5-9242-09173F13E4C5 n4:271B595D-363D-11E5-9242-09173F13E4C5 n4:271B595A-363D-11E5-9242-09173F13E4C5 n4:271B595B-363D-11E5-9242-09173F13E4C5 n4:271B5960-363D-11E5-9242-09173F13E4C5 n4:271B5961-363D-11E5-9242-09173F13E4C5 n4:271B595E-363D-11E5-9242-09173F13E4C5 n4:271B595F-363D-11E5-9242-09173F13E4C5 n4:271B5946-363D-11E5-9242-09173F13E4C5 n4:271B5947-363D-11E5-9242-09173F13E4C5 n4:271B5958-363D-11E5-9242-09173F13E4C5 n4:271B5959-363D-11E5-9242-09173F13E4C5 n4:271B5956-363D-11E5-9242-09173F13E4C5 n4:271B5957-363D-11E5-9242-09173F13E4C5 n4:271B5967-363D-11E5-9242-09173F13E4C5 n4:271B5968-363D-11E5-9242-09173F13E4C5 n4:271B5945-363D-11E5-9242-09173F13E4C5 n4:271B5955-363D-11E5-9242-09173F13E4C5 n4:271B5953-363D-11E5-9242-09173F13E4C5 n4:271B5954-363D-11E5-9242-09173F13E4C5 n4:271B594D-363D-11E5-9242-09173F13E4C5 n4:271B594E-363D-11E5-9242-09173F13E4C5 n4:271B594B-363D-11E5-9242-09173F13E4C5 n4:271B594C-363D-11E5-9242-09173F13E4C5 n4:271B5951-363D-11E5-9242-09173F13E4C5 n4:271B5952-363D-11E5-9242-09173F13E4C5 n4:271B594F-363D-11E5-9242-09173F13E4C5 n4:271B5950-363D-11E5-9242-09173F13E4C5 n4:271B5964-363D-11E5-9242-09173F13E4C5 n4:271B5965-363D-11E5-9242-09173F13E4C5 n4:271B5962-363D-11E5-9242-09173F13E4C5 n4:271B5963-363D-11E5-9242-09173F13E4C5 n4:271B5966-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Chlordiazepoxide is excreted in the urine, with 1% to 2% unchanged and 3% to 6% as conjugate.
n3:synonym
Libritabs 7-chloro-2-Methylamino-5-phenyl-3H-1,4-benzodiazepin-4-oxide Multum Clopoxide Helogaphen Chlordiazepoxide base CDP Chloradiazepoxide Silibrin Tropium Chlordiazepoxidum Risolid Methaminodiazepoxide
n3:toxicity
LD<sub>50</sub>=537 mg/kg (Orally in rats). Signs of overdose include respiratory depression, muscle weakness, somnolence (general depressed activity).
n5:hasAHFSCode
n14:28-24-08
n3:foodInteraction
Take without regard to meals. Avoid alcohol.
n3:mixture
n15:271B5944-363D-11E5-9242-09173F13E4C5 n15:271B5942-363D-11E5-9242-09173F13E4C5 n15:271B5943-363D-11E5-9242-09173F13E4C5 n15:271B5940-363D-11E5-9242-09173F13E4C5 n15:271B5941-363D-11E5-9242-09173F13E4C5
n3:salt
n3:synthesisReference
Sternbach, L.H.; US. Patent 2,893,992; July 7,1959; assigned to Hoffmann-LaRoche, Inc.
foaf:page
n8:chlordiazepoxide.html n12:lib1225.shtml n16:chlordia.htm
n3:IUPAC-Name
n9:271B599A-363D-11E5-9242-09173F13E4C5
n3:InChI
n9:271B59A0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n9:271B599F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n9:271B599C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n9:271B599D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n9:271B599E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n9:271B5998-363D-11E5-9242-09173F13E4C5 n9:271B59B0-363D-11E5-9242-09173F13E4C5
n3:logP
n9:271B5996-363D-11E5-9242-09173F13E4C5 n9:271B5999-363D-11E5-9242-09173F13E4C5 n9:271B59B2-363D-11E5-9242-09173F13E4C5
n3:logS
n9:271B5997-363D-11E5-9242-09173F13E4C5
n3:pKa
n9:271B59B3-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n6:N05BA02
n3:H-Bond-Acceptor-Count
n9:271B59A6-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n9:271B59A7-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n9:271B59A1-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n9:271B59A2-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n9:271B59A4-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n9:271B59A3-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n9:271B59A5-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
58-25-3
n3:category
n3:containedIn
n13:271B598D-363D-11E5-9242-09173F13E4C5 n13:271B598E-363D-11E5-9242-09173F13E4C5 n13:271B598B-363D-11E5-9242-09173F13E4C5 n13:271B598C-363D-11E5-9242-09173F13E4C5 n13:271B598F-363D-11E5-9242-09173F13E4C5 n13:271B5985-363D-11E5-9242-09173F13E4C5 n13:271B5986-363D-11E5-9242-09173F13E4C5 n13:271B5983-363D-11E5-9242-09173F13E4C5 n13:271B5984-363D-11E5-9242-09173F13E4C5 n13:271B5989-363D-11E5-9242-09173F13E4C5 n13:271B598A-363D-11E5-9242-09173F13E4C5 n13:271B5987-363D-11E5-9242-09173F13E4C5 n13:271B5988-363D-11E5-9242-09173F13E4C5 n13:271B5981-363D-11E5-9242-09173F13E4C5 n13:271B5982-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n9:271B59AC-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n9:271B59AE-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n9:271B59AF-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n9:271B59B1-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n9:271B59AB-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n9:271B59AA-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n9:271B59AD-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n9:271B599B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n9:271B59A8-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n9:271B59A9-363D-11E5-9242-09173F13E4C5